trending Market Intelligence /marketintelligence/en/news-insights/trending/jOQx2M8Qj7s2MZP0g9HsFw2 content esgSubNav
In This List

Takeda completes acquisition of Shire

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Takeda completes acquisition of Shire

Japan's biggest drugmaker Takeda Pharmaceutical Co. Ltd. completed its £46 billion acquisition of Dublin-based Shire plc.

The deal has been approved by the Royal Court of Jersey, shareholders of both companies, the EU and the Japan Fair Trade Commission.

The merged entity — a biopharmaceutical giant focused on oncology, gastroenterology, neuroscience and rare diseases — has an annual revenue is over $30 billion, with a geographic footprint spanning about 80 countries, Takeda said in a news release.

Takeda said it is confident it can return to a net debt to EBITDA ratio of 2.0x or less within three to five years following the acquisition, which it funded using permanent financing. The company previously disclosed $10 billion worth of planned divestitures, likely excluding its over-the-counter drug unit, to ease debt burden from the Shire transaction.

Integration is ongoing, and being led by Takeda's executive team.